[From aidsmap, March 8, 2019] “35% of sexually active gay and bisexual men used PrEP, or pre-exposure prophylaxis, to prevent HIV in 2017, according to a new study from the Centers for Disease Control and Prevention, NBCNews reports.” For more, click here.
Over a Third of Gay and Bi Men Now Take PrEP Read More »
[From aidmap, March 6, 2019] “A daily pill containing the newer formulation of tenofovir in combination with emtricitabine (Descovy)had a comparable protective effect to the existing daily pill which contains the older tenofovir and emtricitabine (Truvada), Dr Brad Hare of the Kaiser Permanente San Francisco Medical Center told the Conference on Retroviruses and Opportunistic Infections (CROI
Descovy is non-inferior to Truvada for daily PrEP Read More »
[From Fortune, March 5, 2019] “Should a biotech giant holding a valuable patent be forced to give it up if doing so would serve the public good? That’s the mounting debate over Gilead Sciences’ hold on an HIV prevention treatment, which some say is too expensive and should be available to all.” For more, click here.
Drug-Company Patents vs. the Public Good: Should the NIH Break This Medication Patent? Read More »
[From CKNW – Simi Sara Show, March 5, 2019] Interview with Dr. Zabrina Brumme “Researchers say a London man appears to be free of the AIDS virus after a stem cell transplant. It’s the second such success. Lead researcher Professor Ravindra Gupta at London’s University College says not only is it difficult finding a donor
Second man seems to be free of AIDS virus after transplant Read More »
[From BBC, February 26, 2019] “Almost 1,900 people have been prescribed a drug which dramatically reduces the chances of being infected with HIV, new figures have shown. Scotland was the first part of the UK to make PrEP (pre-exposure prophylaxis) available on the NHS in July 2017. A report from NHS National Services Scotland said uptake of
PrEP drug uptake ‘exceeds predictions’ Read More »
